United Therapeutics' Ralinepag Success Adds To Long Term Value Story [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. United Therapeutics reported that its drug candidate ralinepag succeeded in a pivotal phase 3 trial for pulmonary arterial hypertension. The study met key efficacy and safety endpoints, including a significant reduction in the risk of clinical worsening for patients. The company plans to pursue regulatory submissions, aiming to position ralinepag as a potential new treatment option. For investors following NasdaqGS:UTHR, this update comes with the share price around $478.16 and a 1-year return of 51.4%. Over 3 years the stock has returned 109.0% and over 5 years 199.8%, which places this new clinical result in the context of a company that has already delivered substantial long-term value creation. The ralinepag phase 3 outcome could become an important part of United Therapeutics' story if regulators ult
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (UTHR) had its price target raised by Cantor Fitzgerald from $525.00 to $625.00. They now have an "overweight" rating on the stock.MarketBeat
- Asylon Robotics Announces New Advisors, Additions to Leadership Team [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of MedicineBusiness Wire
- United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) [Seeking Alpha]Seeking Alpha
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- 3/10/26 - Form 4
- UTHR's page on the SEC website